Chaoneng He
Chinese Academy of Sciences(CN)Zhejiang Cancer Hospital(CN)Hangzhou Cancer Hospital(CN)
Publications by Year
Research Areas
Pain Management and Opioid Use, Pharmacological Effects and Toxicity Studies, Nanoparticle-Based Drug Delivery, Antibiotic Resistance in Bacteria, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Methadone switching for refractory cancer pain(2022)18 cited
- → Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study(2024)8 cited
- → A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma(2023)6 cited
- → Cost-effectiveness of PARP inhibitors in malignancies: A systematic review(2022)5 cited
- → Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer(2023)4 cited
- → Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer(2024)3 cited
- → Thromboembolic Risk of Thrombopoietin Receptor Agonists for Adult Primary Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis Integrating Randomized Controlled Trials and Prospective Evidence(2025)1 cited
- → Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China(2024)1 cited
- → Reply to “A better interpretation of data regarding the opioid switching to methadone”(2023)
- → Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis(2024)